Thomas Leggett, Chief Financial Officer at Stoke Therapeutics, Inc. (STOK), sold 9,119 shares at $32.74 ($293K) on 2026-03-17, disclosed to the SEC on 2026-03-19.
Open-market sale of $293k STOK by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.74 | 1,274 | $42K | 14.2% |
| 2 | $32.74 | 1,274 | $42K | 14.2% |
| 3 | $33.38 | 922 | $31K | 10.5% |
| 4 | $33.38 | 922 | $31K | 10.5% |
| 5 | $31.28 | 2,173 | $68K | 23.2% |
| 6 | $31.28 | 2,173 |
| $68K |
| 23.2% |
| 7 | $31.79 | 172 | $5K | 1.9% |
| 8 | $31.79 | 172 | $5K | 1.9% |
| 9 | $32.85 | 37 | $1K | 0.4% |
| Total | $32.14 avg | 9,119 | $293K | 100% |
| Filing → |
| BDTX | SELL | 2020-11-12 | $99K | — | Filing → |
| BDTX | SELL | 2020-10-09 | $101K | — | Filing → |
| BDTX | SELL | 2020-09-16 | $93K | — | Filing → |